Find resources and support

Demonstrated success with our collaborations

Each collaboration with us is unique and maximizes the potential to get more patients screened for colorectal cancer (CRC).
Case study: Naples Comprehensive Health (NCH)

The CRC screening rate for NCH grew by 23% from 2018 to 2022.1

Case study summary
Naples Comprehensive Health (NCH)1
Overview
Following the transition to a new EHR system and a comprehensive review of their CRC screening processes (in collaboration with Exact Sciences), NCH was able to improve their CRC screening rates .
Results
As of 2022, NCH reported that 80.15% of eligible patients had undergone CRC screening. Compared with a 2018 review, it represented a +23% improvement in screening rates at NCH.
How they did it
  • Introduced several workflow enhancements aimed at proactively identifying patients eligible for CRC screening, facilitating discussions between patients and healthcare providers (HCPs) about appropriate screening options, and simplifying the ordering of screening tests.
  • Enacted several strategies, including comprehensive training and onboarding at the onset, as well as a mentorship program to support the transition across clinical sites.

References

  1. Data on file. July 2024. NCH CRC Screening Case Study. Exact Sciences Corporation. Madison, WI.
Case study: Geisinger Health

“Our system is happy we made this choice because it will set up our patients for success at a time when staffing resources are severely curtailed.”2

—Cybele Pacheco, MD, Director of Senior Focused Care, Geisinger Health2
Case study summary
Geisinger Health
Overview
Geisinger Health prioritized the Cologuard® test as its first-line noninvasive option for average-risk patients3
Results
Achieved 70% colorectal cancer (CRC) screening rates
How they did it
  • Drove engagement and alignment across internal stakeholders
  • Supported informed decision-making with actionable tools
  • Developed systematic quality improvement protocols via health information technology (HIT) utilization and electronic health record (EHR) optimization

References

  1. Data on file. May 2024. Geisinger Case Study. Exact Sciences Corporation. Madison, WI.
Case study: Sanitas Medical Center

The CRC screening rate for Sanitas Medical Center grew from 34% in 2018 to 72% by 2022.3

Case study summary
Sanitas Medical Center
Overview
Sanitas Medical Center reached eligible patients in a diverse community through a multidisciplinary CRC screening program3
Results
111% increase in CRC screening rates in less than 4 years
How they did it
  • Educated and communicated to patients in their native language
  • Established an Electronic Health Record (EHR) interface that allowed providers to order tests and receive results directly into patients’ charts
  • Identified and reviewed key CRC screening performance metrics and aligned results against the company’s quality goals

References

  1. Data on file. July 2024. Sanitas Case Study. Exact Sciences Corporation. Madison, WI.
Smiling customer service representative talking to someone with a headset on.
Support for health system providers and patients
  • Our Patient Navigation Program (in English and Spanish) can help improve screening rates (observed 22% increase4*) by providing reminders and resources to help patients successfully complete screening
  • Dedicated Customer Care Center to get information related to orders, Health Insurance Portability and Accountability Act (HIPAA) concerns, or other screening questions
  • We have extensive resources to inform, educate, and guide your providers and patients. Download our example screening options flyer in English or Spanish.
  1. Based on internal data from February 11, 2022, to September 5, 2022, that compared eligible patients who received outreach from the patient navigation program with a small control sample that did not in order to evaluate program effectiveness.4

Successful strategies to improve CRC screening

Learn more about the successful strategies health systems are using to improve CRC screening rates, and how we support providers and patients.
Health Information Technology (HIT) Optimization and the Fight Against Colorectal Cancer (Becker's Executive Summary)

Connect with us to learn how we can support your CRC screening goals

References

  1. Data on file. July 2024. NCH CRC Screening Case Study. Exact Sciences Corporation. Madison, WI.
  2. Data on file. May 2024. Geisinger Case Study. Exact Sciences Corporation. Madison, WI.
  3. Data on file. July 2024. Sanitas Case Study. Exact Sciences Corporation. Madison, WI.
  4. Data on file. Exact Sciences Corporation. Madison, WI.

Indications and Important Risk Information

The Cologuard® test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by colonoscopy. The Cologuard test is indicated to screen adults of either sex, 45 years or older, who are at typical average risk for CRC. The Cologuard test is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

The Cologuard test is not for high-risk individuals, including patients with a personal history of colorectal cancer and adenomas; have had a positive result from another colorectal cancer screening method within the last 6 months; have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease; or have a family history of colorectal cancer, or certain hereditary syndromes.

Positive Cologuard results should be referred to colonoscopy. A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient.

False positives and false negatives do occur. In a clinical study, 13% of patients without colorectal cancer or advanced adenomas received a positive result (false positive) and 8% of patients with cancer received a negative result (false negative). The clinical validation study was conducted in patients 50 years of age and older. Cologuard test performance in patients ages 45 to 49 years was estimated by sub-group analysis of near-age groups.

Cologuard test performance when used for repeat testing has not been evaluated or established. Rx only